We are live on ! Find out more
AMRI

Albany Molecular Research Inc
AMRI

Delisted

AMRI was delisted on the 31st of August, 2017.

143 hedge funds and large institutions have $669M invested in Albany Molecular Research Inc in 2014 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 46 increasing their positions, 42 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

85% more call options, than puts

Call options by funds: $1.95M | Put options by funds: $1.05M

79% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 14

22% more capital invested

Capital invested by funds: $548M → $669M (+$122M)

8% more funds holding

Funds holding: 132143 (+11)

10% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 42

Holders
143
Holders Change
+11
Holders Change %
+8.33%
% of All Funds
4.15%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.12%
New
25
Increased
46
Reduced
42
Closed
14
Calls
$1.95M
Puts
$1.05M
Net Calls
+$899K
Net Calls Change
-$5.29M
Name Holding Trade Value Shares
Change
Change in
Stake
Dimensional Fund Advisors
1
Dimensional Fund Advisors
Texas
$60.2M +$234K +11,442 +0.4%
Morgan Stanley
2
Morgan Stanley
New York
$36.9M +$19.3M +942,089 +129%
BFA
3
BlackRock Fund Advisors
California
$35.9M +$2.24M +109,289 +7%
HM
4
HealthCor Management
New York
$30.9M +$10.8M +525,000 +60%
PIP
5
Permian Investment Partners
Texas
$30M +$14.1M +690,709 +103%
EWM
6
Evercore Wealth Management
New York
$28.9M -$496K -24,200 -2%
Wellington Management Group
7
Wellington Management Group
Massachusetts
$27.2M -$6.79M -331,421 -21%
VAM
8
Visium Asset Management
New York
$26.5M -$19.9M -970,000 -45%
Acadian Asset Management
9
Acadian Asset Management
Massachusetts
$25.9M -$1.75M -85,506 -7%
RA
10
Royce & Associates
New York
$25.2M -$3.54M -172,940 -13%
Millennium Management
11
Millennium Management
New York
$20.5M +$396K +19,343 +2%
Vanguard Group
12
Vanguard Group
Pennsylvania
$20.3M +$989K +48,275 +6%
Allianz Asset Management
13
Allianz Asset Management
Germany
$20.1M +$2.03M +99,153 +12%
ACM
14
American Capital Management
New York
$19.4M -$852K -41,600 -5%
BM
15
Bridger Management
New York
$18M +$16.7M +813,934 New
BIT
16
BlackRock Institutional Trust
California
$16.3M +$164K +8,023 +1%
WIC
17
Wood Investment Counsel
Colorado
$16.2M +$15M +733,328 New
RFC
18
Russell Frank Company
Washington
$12.4M -$88K -4,298 -0.8%
CPIM
19
Columbia Partners Investment Management
Virginia
$12.3M +$5.31M +259,176 +87%
IGM
20
Incline Global Management
New York
$11.4M +$10.6M +515,923 New
HVC
21
Healthcare Value Capital
New Jersey
$11M
DCM
22
Decade Capital Management
New York
$8.83M -$5.3M -258,934 -39%
NAM
23
Netols Asset Management
Wisconsin
$8.72M -$551K -26,902 -6%
State Street
24
State Street
Massachusetts
$8.62M +$142K +6,957 +2%
SLCM
25
Seven Locks Capital Management
New York
$7.76M +$2.95M +143,900 +69%

AMRI Hedge Fund Activity: Q3 2014 in Review

143 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Albany Molecular Research Inc (AMRI) for Q3 2014, worth a combined $669M — up 22% from $548M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new AMRI positions and 14 closed out — a net gain of 11 holders — while 46 added to existing stakes and 42 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $19.3M. The largest seller was Visium Asset Management, cutting an estimated $19.9M.

  • 143 institutional investors held Albany Molecular Research Inc (AMRI) as of Q3 2014, up from 132 in Q2 2014.
  • Funds reported $669M of Albany Molecular Research Inc stock for Q3 2014, up 22% quarter-over-quarter.
  • 25 funds opened new Albany Molecular Research Inc positions in Q3 2014 and 14 closed out, a net change of +11 holders.
  • The largest Albany Molecular Research Inc buyer in Q3 2014 was Morgan Stanley, an estimated $19.3M added.
  • The largest Albany Molecular Research Inc seller in Q3 2014 was Visium Asset Management, an estimated $19.9M sold.

Based on aggregated 13F filings for Q3 2014.